Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results

被引：0
|
作者：
Pettengell, Ruth [1 ]
Zinzani, Pier Luigi [2 ]
Narayanan, Geetha [3 ]
de Mendoza, Fernando Hurtado [4 ]
Digumarti, Raghunadharao [5 ]
Gomez, Henry [6 ]
Coiffier, Bertrand [7 ]
Schiller, Gary [8 ]
Rizzieri, David A. [9 ]
Cernohous, Paul [10 ]
Wang, Lixia [10 ]
Singer, Jack [10 ]
机构：
[1] St Georges Univ London, London, England
[2] Ist Ematol, Policlin S Orsola, Bologna, Italy
[3] Reg Canc Ctr, Div Med Oncol, Thiruvananthapuram, Kerala, India
[4] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[5] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[6] Hosp Edgardo Rebagliati Martins, Lima, Peru
[7] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[8] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[9] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA
[10] Cell Therapeut Inc, Seattle, WA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1168 / 1169
页数：2
相关论文
共 47 条
  • [21] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Jurczak, W.
    Zinzani, P. L.
    Gaidano, G.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Ambarkhane, S.
    Winderlich, M.
    Endell, J.
    Blum, K.
    HAEMATOLOGICA, 2016, 101 : 317 - 317
  • [22] Result of a Phase 3 Randomised Multicenter Study Comparing Pixantrone plus Rituximab with Gemcitabine plus Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation
    Salles, Gilles Andre
    Jurczak, Wojciech
    Andorsky, David J.
    Quick, Donald P.
    Singer, Jack W.
    Singh, Simran Bedi
    Wang, Lixia
    Egorov, Anton
    Gabarroca, Christine
    Pettengell, Ruth
    BLOOD, 2018, 132
  • [23] Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study
    Shi, Yuan-Kai
    Hong, Xiao-Nan
    Yang, Jian-Liang
    Xu, Wei
    Huang, Hui-Qiang
    Xiao, Xiu-Bin
    Zhu, Jun
    Zhou, Dao-Bin
    Han, Xiao-Hong
    Wu, Jian-Qiu
    Zhang, Ming-Zhi
    Jin, Jie
    Ke, Xiao-Yan
    Li, Wei
    Wu, De-Pei
    Yang, Shen-Miao
    Du, Xin
    Jia, Yong-Qian
    Liu, Ai-Chun
    Liu, Dai-Hong
    Shen, Zhi-Xiang
    Zhang, Lian-Sheng
    James, Leonard
    Hellriegel, Edward
    CHINESE MEDICAL JOURNAL, 2021, 134 (11) : 1299 - 1309
  • [24] A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
    Morschhauser, Franck
    Fitoussi, Olivier
    Haioun, Corinne
    Thieblemont, Catherine
    Quach, Hang
    Delarue, Richard
    Glaisner, Sylvie
    Gabarre, Jean
    Bosly, Andre
    Lister, John
    Li, Ju
    Coiffier, Bertrand
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2869 - 2876
  • [25] Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)
    Pettengell, Ruth
    Dlugosz-Danecka, Monika
    Andorsky, David
    Belada, David
    Georgiev, Pencho
    Quick, Donald
    Singer, Jack W.
    Singh, Simran B.
    Pallis, Athanasios
    Egorov, Anton
    Salles, Gilles
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) : 240 - 248
  • [26] Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Ambarkhane, Sumeet
    Winderlich, Mark
    Dirnberger-Hertweck, Maren
    Endell, Jan
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [27] Preliminary results of a phase I/II trial of BBR-2778 (Pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, L
    Liebmann, J
    Modiano, M
    Cohen, GI
    Pro, B
    Romaguera, J
    Davite, C
    Lymboura, M
    Comis, S
    Laffranchi, BL
    BLOOD, 2004, 104 (11) : 373A - 373A
  • [28] MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
    Andorsky, David J.
    Cataruozolo, Patricia E.
    Mouro, Jorge L.
    Li, Ju
    Fustier, Pierre
    Foon, Kenneth A.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Oral tipifarnib (R115777) has single agent anti-tumor activity in patients with relapsed aggressive non-hodgkin lymphoma (NHL): Results of a phase II trial in the university of Iowa/Mayo clinic lymphoma SPORE (CA97274).
    Witzig, Thomas E.
    Maurer, Matthew J.
    Johnston, Patrick B.
    Colgan, Joseph P.
    Kaufmann, Scott H.
    Inwards, David J.
    Micallef, Ivana N.
    Ansell, Stephen M.
    Zent, Clive S.
    Allmer, Cristine
    Weiner, George J.
    Wooldridge, James E.
    Link, Brian K.
    Habermann, Thomas M.
    BLOOD, 2006, 108 (11) : 160A - 160A
  • [30] Salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab: Preliminary results of a multicenter phase it trial.
    Mey, U
    Flieger, D
    Birkmann, J
    Ho, A
    Huhn, D
    Kaiser, U
    Ko, Y
    Kraemer, A
    Neubauer, A
    Wilhelm, M
    Hahn, C
    Haarmann, G
    Glasmacher, A
    Schmidt-Wolf, I
    BLOOD, 2002, 100 (11) : 309B - 309B
12345